Christopher R. O'Dea
Ironwood Pharmaceuticals
6 Papers
7 Citations
Christopher R. O'Dea is an academic researcher from Ironwood Pharmaceuticals. The author has contributed to research in topics: Linaclotide & Internal medicine. The author has an hindex of 3, co-authored 6 publications.
Chat about Author
Papers
Efficacy and safety of linaclotide for opioid-induced constipation in patients with chronic noncancer pain syndromes from a phase 2 randomized study
Darren M. Brenner,Charles Argoff,Susan M. Fox,Wieslaw Bochenek,Patricia D'Astoli,Rick Blakesley,David S. Reasner,Christopher R. O'Dea,Brooks D. Cash +8 more
TL;DR: In patients with chronic noncancer pain and opioid-induced constipation, linaclotide significantly improved stool consistency, straining, abdominal bloating, and treatment satisfaction vs placebo and was well tolerated.
13
875 - Iw-3718, a Novel Gastric-Retentive Bile Acid Sequestrant, Improved Heartburn and Regurgitation Symptoms in Patients with Persistent Gerd Despite PPI Treatment: A Double-Blind, Placebo-Controlled Study
Michael F. Vaezi,Ronnie Fass,Nimish Vakil,Robert S. Mittleman,Michael J. Hall,David S. Reasner,James Z. Shao,Yan Chen,Lara Lane,Christopher R. O'Dea,Mark G. Currie +10 more
5
Evaluation of Daily GI Symptoms in a Phase 2A Study of IW-9179 in Functional Dyspepsia: 2197
Jan Tack,Donald A. Fitch,James Z. Shao,Christopher R. O'Dea,Mark G. Currie,Jeffrey M. Johnston +5 more
TL;DR: Primary site of disease may be an important prognostic factor in patients with PGI-FL and further examination of the biological diff erences between each primary site are needed in the future.
2
Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial
Philip Schoenfeld,Brian E. Lacy,William D. Chey,Anthony Lembo,Caroline B. Kurtz,David S. Reasner,Wieslaw Bochenek,Kenneth Tripp,Mark G. Currie,Susan M. Fox,Rick Blakesley,Christopher R. O'Dea,Nicholas Omniewski,Michael Hall +13 more
TL;DR: Once-daily linaclotide 72 μg significantly improved CIC symptoms in both men and women with a low rate of discontinuation due to diarrhea over 12 weeks of treatment.
Targeted Delivery of Linaclotide to Specific Areas of The Intestine Affects Clinical Efficacy in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)
William D. Chey,Paul Chamberlin,Wieslaw Bochenek,Kenneth Tripp,Carolyn S. Higgins,Nicholas Omniewski,Susan M. Fox,Michael J. Hall,Ahmad Hashash,Matthew Miller,Christopher R. O'Dea,Mark G. Currie +11 more